The approval is supported by data from clinical trials, including pharmacodynamic and pharmacokinetic responses in adults and ...

Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, today announced it is proceeding with a Phase 1 clinical trial ...

Celon Pharma’s PDE10A inhibitor has reduced involuntary movements in a phase 2 trial of individuals with Parkinson’s disease.

AvailTM trial exceeded enrollment target; topline results expected in Q3 2025CARMEL, Ind., March 03, 2025 (GLOBE NEWSWIRE) -- ...

Q4 2024 Earnings Call Transcript March 4, 2025 Amylyx Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is ...

在非小细胞肺癌（NSCLC）患者中，原发 MET 扩增较为少见，且与不良预后相关[1]。随着 MET 抑制剂的问世和临床研究的不断探索，为原发 MET 扩增 NSCLC 患者带来了新的治疗希望。本期「In China For Global - MET ...

Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, ...

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients ...

Dr. Chris VanDeusen, Chief Scientific Officer, will present “TCR-Nck Modulators: Pioneering Oral Modulation of T Cell Receptor Activation Holding the Promise of Treating Dermatologic Diseases,” ...

Implantation of drug-eluting stents (DESs) remains central to percutaneous coronary intervention (PCI) for acute coronary ...

The locus coeruleus noradrenergic system could offer a promising avenue for treating insomnia with medication, especially in ...

Under terms of the deal, Gubra will receive an initial $350 million payment and could earn up to $1.875 billion more in ...